NOTICE: This is an archived press release. Information contained on this page may be outdated. Please refer to our latest press releases for up-to-date information.

Post date: June 18 2004

Statement Regarding Decision By Glaxosmithkline To Post Summaries Of Clinical Trial Results

New York State Attorney General Spitzer today issued the following statement in response to the decision by GlaxoSmithKline to post summaries of clinical trial results.

"This is another positive step towards providing important and necessary information to doctors and the public. The availability of this information is in the best interest of the consumer. We will continue our efforts to change industry practice in this area."

Spitzer sued the GlaxoSmithKline on June 2 alleging that the company engaged in repeated and persistent fraud by concealing and failing to disclose to physicians important information about the safety and efficacy of Paxil, a drug used to treat depression. The lawsuit alleges that, starting in 1998, GSK engaged in a concerted effort to withhold negative information concerning Paxil and misrepresent data concerning Paxil's safety and efficacy when prescribed for depression in children and adolescents.